Publication | Closed Access

Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma

Tumor BiologyHealth SciencesHuman Hepatocellular CarcinomaMetabolic ReprogrammingMedicineβ-Catenin/c-myc SignalingMetabolic RemodelingCell BiologyLiver CancerMetabolic SignalingCancer BiologyRadiation OncologyHepatocellular CarcinomaCancer ResearchCancer MetabolismDrug Resistance